Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges Publisher Pubmed

Razeghian E¹ ; Suksatan W² ; Sulaiman Rahman H^{3, 4} ; Bokov DO^{5, 6} ; Abdelbasset WK^{7, 8} ; Hassanzadeh A⁹ ; Marofi F¹⁰ ; Yazdanifar M¹¹ ; Jarahian M¹²

Show Affiliations

1. Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, Iran
2. Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand
3. Department of Physiology, College of Medicine, University of Suleimanyah, Suleimanyah, Iraq
4. Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaimaniyah, Iraq
5. Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation
6. Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation
7. Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia
8. Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt
9. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
10. Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran
11. Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, United States
12. Toxicology and Chemotherapy Unit (G401), German Cancer Research Center, Heidelberg, Germany

Source: Frontiers in Immunology Published:2021

Abstract

The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted rapidly evolving attention as a cancer treatment modality because of its competence to selectively eliminate tumor cells without instigating toxicity in vivo. TRAIL has revealed encouraging promise in preclinical reports in animal models as a cancer treatment option; however, the foremost constraint of the TRAIL therapy is the advancement of TRAIL resistance through a myriad of mechanisms in tumor cells. Investigations have documented that improvement of the expression of anti-apoptotic proteins and survival or proliferation involved signaling pathways concurrently suppressing the expression of pro-apoptotic proteins along with down-regulation of expression of TRAILR1 and TRAILR2, also known as death receptor 4 and 5 (DR4/5) are reliable for tumor cells resistance to TRAIL. Therefore, it seems that the development of a therapeutic approach for overcoming TRAIL resistance is of paramount importance. Studies currently have shown that combined treatment with anti-tumor agents, ranging from synthetic agents to natural products, and TRAIL could result in induction of apoptosis in TRAIL-resistant cells. Also, human mesenchymal stem/stromal cells (MSCs) engineered to generate and deliver TRAIL can provide both targeted and continued delivery of this apoptosis-inducing cytokine. Similarly, nanoparticle (NPs)-based TRAIL delivery offers novel platforms to defeat barricades to TRAIL therapeutic delivery. In the current review, we will focus on underlying mechanisms contributed to inducing resistance to TRAIL in tumor cells, and also discuss recent findings concerning the therapeutic efficacy of combined treatment of TRAIL with other antitumor compounds, and also TRAIL-delivery using human MSCs and NPs to overcome tumor cells resistance to TRAIL. © Copyright © 2021 Razeghian, Suksatan, Sulaiman Rahman, Bokov, Abdelbasset, Hassanzadeh, Marofi, Yazdanifar and Jarahian.

Related Docs

View other Related Docs

1. Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy, Frontiers in Cell and Developmental Biology (2021)

2. Quercetin Elicits Proapoptotic Effect Through Downregulation of Antiapoptotic and Upregulation of Proapoptotic Genes in Human Myeloid Leukemia Kg-1 Cells, Annals of Cancer Research and Therapy (2021)

3. Anti-Tumour Effects of Trail-Expressing Human Placental Derived Mesenchymal Stem Cells With Curcumin-Loaded Chitosan Nanoparticles in a Mice Model of Triple Negative Breast Cancer, Artificial Cells# Nanomedicine and Biotechnology (2018)

4. Mesenchymal Stem Cells As Professional Actors in Gastrointestinal Cancer Therapy: From Naive to Genetically Modified, Iranian Journal of Basic Medical Sciences (2021)

5. Cytokine Sustained Delivery for Cancer Therapy; Special Focus on Stem Cell- and Biomaterial- Based Delivery Methods, Pathology Research and Practice (2023)

6. Nanotechnology and Bioengineering Approaches to Improve the Potency of Mesenchymal Stem Cell As an Off-The-Shelf Versatile Tumor Delivery Vehicle, Medicinal Research Reviews (2024)

7. Mesenchymal Stem Cells: A New Platform for Targeting Suicide Genes in Cancer, Journal of Cellular Physiology (2018)

8. An Overview on Display Systems (Phage, Bacterial, and Yeast Display) for Production of Anticancer Antibodies; Advantages and Disadvantages, International Journal of Biological Macromolecules (2022)

Experts (# of related papers)

View all Related Experts

Mohammad Vasei (1)

Mohammad Reza Khorramizadeh (1)

Style	Citing Format
MLA	Razeghian E, et al.. "Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges." Frontiers in Immunology, vol. 12, no. , 2021, pp. -.
APA	Razeghian E, Suksatan W, Sulaiman Rahman H, Bokov DO, Abdelbasset WK, Hassanzadeh A, Marofi F, Yazdanifar M, Jarahian M (2021). Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. Frontiers in Immunology, 12(), -.
Chicago	Razeghian E, Suksatan W, Sulaiman Rahman H, Bokov DO, Abdelbasset WK, Hassanzadeh A, Marofi F, Yazdanifar M, Jarahian M. "Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges." Frontiers in Immunology 12, no. (2021): -.
Harvard	Razeghian E et al. (2021) 'Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges', Frontiers in Immunology, 12(), pp. -.
Vancouver	Razeghian E, Suksatan W, Sulaiman Rahman H, Bokov DO, Abdelbasset WK, Hassanzadeh A, et al.. Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. Frontiers in Immunology. 2021;12():-.
BibTex	@article{ author = {Razeghian E and Suksatan W and Sulaiman Rahman H and Bokov DO and Abdelbasset WK and Hassanzadeh A and Marofi F and Yazdanifar M and Jarahian M}, title = {Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges}, journal = {Frontiers in Immunology}, volume = {12}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Razeghian E AU - Suksatan W AU - Sulaiman Rahman H AU - Bokov DO AU - Abdelbasset WK AU - Hassanzadeh A AU - Marofi F AU - Yazdanifar M AU - Jarahian M TI - Harnessing Trail-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges JO - Frontiers in Immunology VL - 12 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract